Sugi Predict

Sugi Predict / Compounds / SCHEMBL787718

SCHEMBL787718

SCHEMBL787718

O=C(O)c1cc(B(O)O)ccc1Cl

nearest known ligand 0.59

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ ALDH1A1 P00352 4/20 0.59
▸ TP53 P04637 1/20 0.59
▸ TDP1 Q9NUW8 4/20 0.50
▸ POLB P06746 4/20 0.50
▸ KDM4E B2RXH2 2/20 0.50
▸ NPC1 O15118 1/20 0.50
▸ MAPT P10636 1/20 0.50
▸ RAB9A P51151 1/20 0.50
▸ LMNA P02545 1/20 0.49
▸ CTSB P07858 1/20 0.46
▸ TTR P02766 2/20 0.46
▸ KMT2A Q03164 2/20 0.44
▸ TSHR P16473 3/20 0.44
▸ CASP1 P29466 1/20 0.44
▸ SMN1; SMN2 Q16637 1/20 0.44
▸ GRIK1 P39086 1/20 0.42
▸ GRIA1 P42261 1/20 0.42
▸ GRIA2 P42262 1/20 0.42
▸ GRIA3 P42263 1/20 0.42
▸ GRIA4 P48058 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29954641 1.00 ALDH1A1 (0.59) ALDH1A1TP53TDP1POLBKDM4E
SCHEMBL396220 0.84 TSHR (0.59) ALDH1A1TP53TDP1POLBKDM4E
SCHEMBL29758174 0.84 TSHR (0.59) ALDH1A1TP53TDP1POLBKDM4E
SCHEMBL1787715 0.82 ALDH1A1 (0.47) ALDH1A1TP53TDP1POLBKDM4E
SCHEMBL786961 0.81 MGLL (0.56) ALDH1A1TP53TDP1POLBKDM4E
SCHEMBL918043 0.81 ALDH1A1 (0.44) ALDH1A1TDP1POLBKDM4ETTR
SCHEMBL30807652 0.81 ALDH1A1 (0.44) ALDH1A1TDP1POLBKDM4ETTR
SCHEMBL14875768 0.78 ALDH1A1 (0.60) ALDH1A1TP53POLBKDM4ENPC1
SCHEMBL660617 0.78 MEN1 (0.50) ALDH1A1TP53KDM4EMAPTLMNA
SCHEMBL29953067 0.78 SMN1; SMN2 (0.51) ALDH1A1KDM4ENPC1MAPTRAB9A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 147 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2025231161-A1 ANTIBIOTIC METHODS AND COMPOSITIONS AI BIO DISCOVERY LLC (US) 2025-11-06 — — WO claimed
US-20250332181-A1 ANTIBIOTIC METHODS AND COMPOSITIONS AI BIO DISCOVERY LLC (US) 2025-10-30 — — US claimed
CN-116712599-A High-tensile wound-healing-promoting antibacterial hydrogel dressing, preparation method and application 江南大学附属医院 2023-09-08 — — CN claimed
US-12637436-B2 Metabotropic glutamate receptor negative allosteric modulators (NAMs) and uses thereof Sanford Burnham Prebys Medical Discovery Institute (US) 2026-05-26 — — US disclosed
WO-2026041663-A1 P2X7 RECEPTOR ANTAGONISTS BREYE THERAPEUTICS APS (DK) 2026-02-26 — — WO disclosed
WO-2025231161-A1 ANTIBIOTIC METHODS AND COMPOSITIONS AI BIO DISCOVERY LLC (US) 2025-11-06 — — WO disclosed
WO-2025231161-A1 ANTIBIOTIC METHODS AND COMPOSITIONS AI BIO DISCOVERY LLC (US) 2025-11-06 — — WO disclosed
US-20250332181-A1 ANTIBIOTIC METHODS AND COMPOSITIONS AI BIO DISCOVERY LLC (US) 2025-10-30 — — US disclosed
US-20250332181-A1 ANTIBIOTIC METHODS AND COMPOSITIONS AI BIO DISCOVERY LLC (US) 2025-10-30 — — US disclosed
US-20250179000-A1 METABOTROPIC GLUTAMATE RECEPTOR POSITIVE ALLOSTERIC MODULATORS (PAMS) AND USES THEREOF Sanford Burnham Prebys Medical Discovery Institute 2025-06-05 — — US disclosed
WO-2025006553-A1 METABOTROPIC GLUTAMATE RECEPTOR POSITIVE ALLOSTERIC MODULATORS AND USES THEREOF Sanford Burnham Prebys Medical Discovery Institute (US) 2025-01-02 — — WO disclosed
US-20100184800-A1 Compounds for the Treatment of Hepatitis C BRISTOL-MYERS SQUIBB COMPANY 2010-07-22 — — US disclosed
US-20100184800-A1 Compounds for the Treatment of Hepatitis C BRISTOL-MYERS SQUIBB COMPANY 2010-07-22 — — US disclosed
US-20100184800-A1 Compounds for the Treatment of Hepatitis C BRISTOL-MYERS SQUIBB COMPANY 2010-07-22 — — US disclosed
US-20100093694-A1 Compounds for the Treatment of Hepatitis C BRISTOL-MYERS SQUIBB COMPANY 2010-04-15 — — US disclosed
WO-2010030592-A1 COMPOUNDS FOR THE TREATMENT OF HEPATITIS C BRISTOL-MYERS SQUIBB COMPANY (US) 2010-03-18 — — WO disclosed
WO-2010030538-A2 COMPOUNDS FOR THE TREATMENT OF HEPATITIS C BRISTOL-MYERS SQUIBB COMPANY (US) 2010-03-18 — — WO disclosed
US-20100063068-A1 Compounds for the Treatment of Hepatitis C BRISTOL-MYERS SQUIBB COMPANY 2010-03-11 — — US disclosed
US-20100063068-A1 Compounds for the Treatment of Hepatitis C BRISTOL-MYERS SQUIBB COMPANY 2010-03-11 — — US disclosed
US-20100063068-A1 Compounds for the Treatment of Hepatitis C BRISTOL-MYERS SQUIBB COMPANY 2010-03-11 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250179000-A1 METABOTROPIC GLUTAMATE RECEPTOR POSITIVE ALLOSTERIC MODULATORS (PAMS) AND USES THEREOF GRM3, GRM2, GRM1 ALDH1A1 4468/4885TP53 4227/4885TDP1 3912/4885
US-20100063068-A1 Compounds for the Treatment of Hepatitis C HAVCR2, HCCS, SLC10A1 ALDH1A1 447/4885TP53 299/4885TDP1 4105/4885
US-20100184800-A1 Compounds for the Treatment of Hepatitis C HAVCR2, HCCS, SLC10A1 ALDH1A1 447/4885TP53 299/4885TDP1 4105/4885
US-20100093694-A1 Compounds for the Treatment of Hepatitis C HAVCR2, HCCS, SLC10A1 ALDH1A1 239/4885TP53 430/4885TDP1 3548/4885
US-20250332181-A1 ANTIBIOTIC METHODS AND COMPOSITIONS CMBL, EBPL, BPGM ALDH1A1 1294/4885TP53 3797/4885TDP1 2729/4885
US-12637436-B2 Metabotropic glutamate receptor negative allosteric modulators (NAMs) and uses thereof GRM3, GRM2, GRM1 ALDH1A1 3385/4885TP53 4838/4885TDP1 4641/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.